Biomarin Pharmaceutical (BMRN) Cash from Operations Growth (5y) (2014 - 2026)
Biomarin Pharmaceutical (BMRN) Cash from Operations Growth (5y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,094.26 Bn | 68,093.97 Bn | - |
| 2 | Nanobiotix | 1,939.09 Bn | 1,939.02 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.34 Bn | 116.09 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.38 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - |
| 8 | Argenx Se | 56.38 Bn | 51.20 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn |
| 10 | Biomarin Pharmaceutical | 11.64 Bn | 9.42 Bn | 571.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.22% |
| Dec 31, 2025 | 56.69% |
| Sep 30, 2025 | 33.73% |
| Jun 30, 2025 | 46.20% |
| Mar 31, 2025 | 68.24% |
| Dec 31, 2024 | 26.48% |
| Sep 30, 2024 | 25.86% |
| Jun 30, 2024 | 47.07% |
| Mar 31, 2024 | 23.35% |
| Dec 31, 2023 | -11.06% |
| Sep 30, 2023 | 23.51% |
| Jun 30, 2023 | 32.41% |
| Mar 31, 2023 | -11.70% |
| Dec 31, 2022 | -14.22% |
| Sep 30, 2022 | 32.83% |
| Jun 30, 2022 | 24.52% |
| Mar 31, 2022 | 10.80% |
| Dec 31, 2021 | 123.07% |
| Sep 30, 2021 | 62.59% |
| Jun 30, 2021 | 30.65% |